From a cancer therapeutics perspective, the substantial tumor growth inhibition observed in our xenografts provides a strong rationale to combine Bcl-xL blockade, using navitoclax or HDAC1–3 inhibition (Supplementary Fig. S4C) with KRASG12C inhibitors in patients with colorectal cancer. Here, BCL2L1 is linked to colorectal cancer.